The major obstacle to human immunodeficiency type 1 virus (HIV-1) eradication is a reservoir of latently infected cells that persists despite long-term antiretroviral therapy (ART) and is maintained through cellular proliferation. Long-lived memory CD4 ϩ T cells with high self-renewal capacity, such as central memory (CM) T cells and stem cell memory (SCM) T cells, are major contributors to the viral reservoir in HIV-infected individuals on ART. The Wnt/␤-catenin signaling pathway regulates the balance between self-renewal and differentiation of SCM and CM T cells, and pharmacological manipulation of this pathway offers an opportunity to interfere with the proliferation of latently infected cells. Here, we evaluated in vivo a novel approach to inhibit self-renewal of SCM and CM CD4 ϩ T cells in the rhesus macaque (RM) model of simian immunodeficiency (SIV) infection. We used an inhibitor of the Wnt/␤-catenin pathway, PRI-724, that blocks the interaction between the coactivator CREB-binding protein (CBP) and ␤-catenin, resulting in the cell fate decision to differentiate rather than proliferate. Our study shows that PRI-724 treatment of ARTsuppressed SIV mac251 -infected RMs resulted in decreased proliferation of SCM and CM T cells and modified the SCM and CM CD4 ϩ T cell transcriptome toward a profile of more differentiated memory T cells. However, short-term treatment with PRI-724 alone did not significantly reduce the size of the viral reservoir. This work demonstrates for the first time that stemness pathways of long-lived memory CD4 ϩ T cells can be pharmacologically modulated in vivo, thus establishing a novel strategy to target HIV persistence. IMPORTANCE Long-lasting CD4 ϩ T cell subsets, such as central memory and stem cell memory CD4 ϩ T cells, represent critical reservoirs for human immunodeficiency virus (HIV) persistence despite suppressive antiretroviral therapy. These cells possess stem cell-like properties of enhanced self-renewal/proliferation, and proliferation of latently infected memory CD4 ϩ T cells plays a key role in maintaining the reservoir over time. Here, we evaluated an innovative strategy targeting the proliferation of long-lived memory CD4 ϩ T cells to reduce viral reservoir stability. Using the rhesus macaque model, we tested a pharmacological inhibitor of the Wnt/␤-catenin signaling pathway that regulates T cell proliferation. Our study shows that administration of the inhibitor PRI-724 decreased the proliferation of SCM and CM CD4 ϩ T cells and promoted a transcriptome enriched in differentiation genes. Although the viral reser-Citation Mavigner M, Zanoni M, Tharp GK, Habib J, Mattingly CR, Lichterfeld M, Nega MT, Vanderford TH, Bosinger SE, Chahroudi A. 2020. Pharmacological modulation of the Wnt/βcatenin pathway inhibits proliferation and promotes differentiation of long-lived memory CD4 + T cells in antiretroviral therapysuppressed simian immunodeficiency virusinfected macaques. J Virol 94:e01094-19.
demonstrated to specifically inhibit the CBP/␤-catenin interaction, thereby selectively blocking the major pathway involved in cell self-renewal while conversely promoting cell differentiation (37) (38) (39) (40) .
Here, we assessed the impact of Wnt pathway modulation on the proliferation of the long-lived SCM and CD4 ϩ T cells using the well-established model of simian immunodeficiency virus (SIV) infection of rhesus macaques (RMs). This in vivo study included 12 SIV-infected RMs in which virus replication was effectively suppressed with a potent, three-drug ART regimen to investigate the effect of PRI-724 administration for a 12-week period. In this preclinical experimental setting, we found that PRI-724 was safe, reduced SCM and CM CD4 ϩ T cell proliferation, and induced changes in the transcriptomic profile of the SCM and CM CD4 ϩ T cells that were indicative of cell differentiation but did not alter the viral reservoir of latently infected CD4 ϩ T cells. This study suggests that targeting the Wnt/␤-catenin pathway is a novel approach to limit proliferation of memory CD4 ϩ T cells that may be complementary to strategies to reduce HIV/SIV persistence in long-lived reservoirs.
RESULTS
Experimental design. Twelve Indian rhesus macaques (RMs), including 5 males and 7 females, were infected intravenously (i.v.) with 10 3 50% tissue culture infective dose (TCID 50 ) of SIV mac251 . Starting at day 11 postinfection (p.i.), all 12 animals were initiated on triple ART consisting of two reverse transcriptase inhibitors (tenofovir [PMPA] and emtricitabine [FTC] ) and one integrase inhibitor (dolutegravir [DTG] ). After 13 to 14 weeks on ART and a plasma viral load suppression of Ͻ80 copies/ml for at least 4 weeks, 8 RMs additionally received the CBP/␤-catenin inhibitor PRI-724, while the 4 remaining RMs were maintained on ART only and served as controls ( Fig. 1) . Among the PRI-724-treated group, 5 RMs received 6 cycles (1 week on/1 week off) of PRI-724 at 10 mg/kg/day administered subcutaneously (s.c.). Based on results from a concurrent dose-ranging study (Fig. 2) , an additional 3 RMs received 12 weeks of uninterrupted PRI-724 at 20 mg/kg/day s.c., a dose that was found to be safe in healthy RMs. As shown in Fig. 3A , following experimental infection with SIV mac251 , the twelve RMs experienced a rapid, exponential increase in viremia, reaching levels of 10 6 to 10 8 SIV RNA copies/ml plasma. ART initiated at day 11 postinfection drastically reduced plasma viral loads to below the assay limit of detection after 3 to 10 weeks of treatment.
Safety profile of PRI-724 administration in ART-suppressed SIV-infected RMs. We first examined clinical and laboratory parameters to assess the safety of PRI-724 administration in this preclinical setting. PRI-724 administration did not affect plasma viral loads, which remained undetectable for the duration of treatment (Fig. 3A) . Depletion of circulating CD4 ϩ T cells was observed in all RMs during acute SIV infection, followed by a partial reconstitution of peripheral CD4 ϩ T cell absolute count and frequency on ART and stable levels during PRI-724 treatment ( Fig. 3B and C dinal assessment of hematological parameters, such as white blood cell (WBC) count, hemoglobin level, and platelet count, showed no significant difference between PRI-724-treated and control groups (Fig. 4A ). Liver and kidney functions did not appear to be adversely impacted by PRI-724 treatment, based on stable serum levels of aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT), and creatinine ( Fig. 4B ), again with no significant differences observed between treatment and control groups. Importantly, PRI-724-treated animals did not experience any clinical adverse events and, despite frequent sedation and blood collections, animal weights did not significantly fluctuate over the course of the treatment period ( Fig. 4C ). Similar results were found in healthy RMs given PRI-724 at both 20 mg/kg/day and 40 mg/kg/day s.c.; however, animals who received PRI-724 at a dose of 80 mg/kg/day s.c. developed significant weight loss, elevations in liver enzymes, and anemia. Intermediate and high dosing regimens were also associated with small subcutaneous abscesses at the injection sites ( Fig. 2B ).
Pharmacological modulation of the Wnt/␤-catenin pathway could potentially affect trilineage hematopoiesis in the bone marrow. To assess for this potential consequence of PRI-724 treatment, we collected bone marrow at selected time points for pathological review. Overall bone marrow cellularity was unaffected by PRI-724, and trilineage hematopoiesis appeared normal, with no significant differences in the frequency of megakaryocytes, myeloid, or erythroid precursors pre-and post-PRI-724 treatment ( Fig.  4D ). Taken together, these results suggest that PRI-724 can be safely administered at doses of 10 to 20 mg/kg/day in ART-treated SIV-infected RMs.
PRI-724 restricts SCM and CM T cell proliferation. The predicted impact of inhibition of the CBP/␤-catenin interaction is a reduction in proliferation/self-renewal of cells utilizing this pathway. To assess the effect of PRI-724 administration on T cell proliferation in vivo, we examined the frequency and absolute count of different subsets of CD4 ϩ and CD8 ϩ memory T cells in peripheral blood before and after treatment with PRI-724, as well as their level of expression of the proliferation marker Ki67. Remarkably, a decrease in the absolute count of SCM and CM CD4 ϩ T cells expressing Ki67 was observed after PRI-724 treatment (Fig. 5A , bottom panels; P ϭ 0.008 and P ϭ 0.05). Similarly, the SCM and CM CD8 ϩ T cells expressing Ki67 declined following PRI-724 treatment, as shown by the frequency (Fig. 5B , top panels; P ϭ 0.05 and P ϭ 0.008) and absolute count (Fig. 5B , bottom panels; P ϭ 0.002 and P ϭ 0.008). No significant changes were seen in the control group over the same period of time. Limited modulation of the levels of long-lived memory T cells was observed following PRI-724 treatment with a decrease in the frequency of SCM CD4 ϩ T cells and absolute count of CM CD8 ϩ T cells ( Fig. 5C and D; P ϭ 0.05, and P ϭ 0.02). After PRI-724 treatment, a negative correlation was observed between proliferation of SCM CD4 ϩ T
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C. E. Fig. 5E ), showing that the PRI-724-related reduction in SCM CD4 ϩ T cell proliferation was associated with an increase in the frequency of progeny CM CD4 ϩ T cells. These results suggest that inhibiting the CBP/␤-catenin interaction both reduces the self-renewal of long-lived memory CD4 ϩ T cells and promotes their differentiation into shorter-lived cells.
D. B.
PRI-724 promotes a differentiation-enriched transcriptome in CM and SCM CD4 ؉ T cells. To define the impact of CBP/␤-catenin interaction inhibition on CD4 ϩ T cells, we assessed the transcriptional profile of populations of naive, SCM, CM, and EM CD4 ϩ T cells sorted from the peripheral blood of the 8 experimental RMs after PRI-724 treatment and at an equivalent time point for the 4 control RMs (gating strategy shown in Fig. 6 ). We used RNA sequencing (RNA-Seq) to determine if PRI-724 treatment modified the transcriptomes of sorted CM and SCM CD4 ϩ T cells to a differentiation-enriched state. Principal component analysis (PCA) demonstrated that the global transcriptomic profile of each cell subset was clearly distinguishable, thus validating our sorting strategy and the sensitivity and accuracy of our approach (Fig. 7A ). Of note, the relative distances between sorted cell subsets showed that SCM and CM CD4 ϩ T cells were more closely related to each other in their gene expression profile than to the other cell populations, confirming previous results obtained with CD8 ϩ T cells (29) . PRI-724-treated and control groups were transcriptionally similar within the naive and EM CD4 ϩ T cell subsets, but they showed more variation within the SCM and CM CD4 ϩ T cell populations, suggesting that the effect of PRI-724 was specific to these cell populations.
We next sought to examine the transcriptomic data for evidence that PRI-724 was able to confer to SCM or CM cells an expression profile consistent with differentiation. We first defined a set of genes that could discriminate SCM from CM cells by contrasting expression profiles in our untreated animals and identifying transcripts that were statistically overexpressed in SCM relative to CM T cells (defined as a false discovery rate [FDR] of Ͻ0.05 and a fold change of Ͼ2). The genes that discriminate between SCM and CM T cells are depicted in Fig. 7B , with naive and EM expression included for reference. We termed this set the "SCM/CM differentiation gene set." We similarly defined a "CM/EM differentiation gene set" by contrasting CM with EM cells from untreated animals using the same gene-filtering criteria (Fig. 7C) .
To test the hypothesis that PRI-724 treatment resulted in systematic upregulation of differentiation genes in SCM T cells from treated animals, we compared the transcriptomes of SCM T cells from the PRI-724-treated animals directly to those of SCM and CM T cells from untreated animals using gene set enrichment analysis (GSEA). Genes that we had identified as being upregulated in CM T cells compared to SCM T cells ("Up in CM vs SCM") were significantly enriched in the SCM T cells of PRI-724-treated animals (FDR Ͻ 0.001; Fig. 8A ). However, genes that we had identified as being downregulated in CM compared to SCM ("Down in CM vs SCM") were not significantly enriched in the SCM of the PRI-724-treated animals (Fig. 8B ). Manual inspection of the leading-edge genes in the "up" and "down" SCM/CM differentiation gene sets showed a similar effect (Fig. 8C ). While variation exists between animals, this heat map provides a visual representation of the intermediate profile of cells transitioning from one differentiation stage to another following PRI-724 treatment.
A similar approach was used to assess CM CD4 ϩ T cells from PRI-724-treated versus control RMs, with both "up" CM/EM differentiation genes and "down" CM/EM differentiation genes being statistically significantly enriched or reduced, respectively, in CM T cells from PRI-724-treated animals ( Fig. 9A and B , P Ͻ 0.001 for both comparisons). The leading-edge gene heat map (Fig. 9C ) again demonstrates a transcriptomic profile of CM CD4 ϩ T cells from PRI-724-treated RMs that is intermediate between those of CM and EM CD4 ϩ T cells of controls, suggesting that these cells were captured during a period of differentiation.
PRI-724 did not reduce the level of cell-associated SIV DNA in memory CD4 ؉ T cells. We then evaluated the impact of the pharmacological inhibition of CBP/␤catenin interaction on the persistent viral reservoir by measuring by PCR the frequency of infection of CD4 ϩ T cell subsets sorted by fluorescence-activated cell sorting (FACS) from the peripheral blood. Most animals from both PRI-724-treated and control groups experienced a decrease in cell-associated SIV DNA in the different subsets of CD4 ϩ T cells at weeks 27 to 28 compared to weeks 15 to 16 after infection, likely related to the expected reduction in virus persistence due to ART. We thus compared the ratios of cell-associated SIV DNA before (weeks 15 to 16) and after PRI-724 treatment (weeks 27 to 28) or over a similar time period in the controls (Fig. 10) . The ratios were similar for each subset (0.15-to 2.3-fold change), suggesting that PRI-724 treatment alone did not significantly reduce the viral reservoir in ART-suppressed SIV-infected RMs.
DISCUSSION
Developing novel strategies to eliminate viral reservoirs that could lead toward a cure or lifelong remission of HIV infection remains a key priority in HIV/AIDS research. The reservoir of latently infected memory CD4 ϩ T cells that persists on long-term ART represents the main barrier to HIV cure. Recent studies establishing clonal expansion of HIV-infected cells as an important mechanism of reservoir maintenance suggest that reaching a functional cure will likely require interference with the proliferation of infected cells, particularly memory CD4 ϩ T cell subsets with long life spans and important clonogenic properties (16, (18) (19) (20) (21) 41 ).
Here, we tested an innovative approach aimed at reducing SIV persistence by inhibiting the self-renewal properties of the long-lived CM and SCM CD4 ϩ T cells. We used the robust nonhuman primate model of SIV infection of RMs to evaluate a small molecule targeting an intracellular signaling pathway controlling cell proliferation. While Wnt inhibition initially raised toxicity concerns, PRI-724, has completed phase Ia 
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Journal of Virology clinical evaluation and has proven to be safe in humans (42) (43) (44) . Previous work in healthy volunteers and oncology patients suggests that pharmacologic inhibition of CBP/␤-catenin may be readily translatable to clinical studies in persons living with HIV.
In the work described here, PRI-724 doses of 10 to 20 mg/kg/day were administered to 8 SIV-infected macaques and an additional 4 uninfected animals without adverse events. The concurrent dose-ranging study indicated that PRI-724 doses of up to 40 mg/kg/day may be safe in healthy macaques, but administration of 80 mg/kg/day of PRI-724 was associated with both clinical and laboratory abnormalities. The administration of PRI-724 to ART-suppressed SIV-infected RMs induced a consistent decline in Ki67 expression in circulating SCM and CM CD4 ϩ and CD8 ϩ T cells. This result suggests that PRI-724 can reduce the proliferation of long-lived memory T cells in vivo. In line with this result, inhibition of CBP/␤-catenin by PRI-724 has been associated with decreased expression of proliferation-related markers in hepatic stellate cells in a murine model of fibrosis (45) . Similarly, other ␤-catenin inhibitors have been shown to reduce Ki67 expression in various cancer models (46) (47) (48) . The antiproliferative capacities of PRI-724 are being further evaluated in several ongoing phase I/II trials in hematological malignancies, pancreatic cancer, and colon cancer. After PRI-724 treatment, a negative correlation was observed in the peripheral blood between proliferation of SCM CD4 ϩ T cells and frequency of CM CD4 ϩ T cells. In a highly dynamic system, the observations that the frequency and absolute count of CM cells remained stable Genes are shown in Data Sets S10, S11, and S12.
while that of CM cells expressing Ki67 declined indicates that pharmacologic inhibition of SCM self-renewal with PRI-724 is also associated with the promotion of SCM differentiation into the less-differentiated CM population.
Using the more comprehensive approach of RNA-Seq, we showed that treatment with PRI-724 led to a consistent programming of gene expression profiles of lessdifferentiated memory CD4 ϩ T cells toward that of more-differentiated cells, with SCM CD4 ϩ T cells exhibiting a transcriptomic profile intermediate to those of SCM and CM CD4 ϩ T cells and CM CD4 ϩ T cells exhibiting a transcriptomic profile intermediate to those of CM and EM CD4 ϩ T cells. Therefore, by using the complementary approaches of flow cytometry and transcriptomic analyses, we demonstrate that interference with the CBP/␤-catenin interaction in vivo results in restricted proliferation and enhanced differentiation of long-lived memory CD4 ϩ T cells. As recent studies using mathematical modeling suggest that antiproliferative therapies used in combination with ART could reduce the time needed to reach a functional cure (41, 49) , the identification of drugs that can safely reduce the proliferation of latently infected cells may be an important step forward.
Pharmacological targeting of CBP/␤-catenin did not induce virus reactivation, as shown by the maintenance of plasma viral loads below the limit of detection following PRI-724 administration in ART-treated SIV-infected RMs. This result was expected, as our approach represents a paradigm shift away from strategies that require latency reversal, i.e., the "shock and kill" approach (50) (51) (52) . Instead, we chose to target the most long-lasting, stem cell-like component of the viral reservoir that can indefinitely repopulate latently infected CD4 ϩ T cells in HIV-infected individuals. Our results indicate that long-lived memory CD4 ϩ T cell differentiation can occur without virus reactivation. While PRI-724 is not specific to SCM and CM T cells (as ␤-catenin is active in other cells, including nonimmunological stem cells), it should be noted that this intervention is more specific, in terms of cellular targets, than the first generation of latency-reversing agents, such as histone deacetylase (HDAC) inhibitors, which have been extensively studied in humans as potential approaches to reduce the virus reservoir. Furthermore, trilineage hematopoiesis was preserved in PRI-724-treated animals, alleviating concern regarding its potential impact on normal cellular development at the tested doses.
ART duration was limited to 13 to 14 weeks before PRI-724 treatment in this pilot experiment, and the decline of cell-associated SIV DNA levels in circulating CD4 ϩ T cell subsets in both PRI-treated and control groups was thus expected as a function of time on ART irrespective of the experimental intervention. Unbiased analyses of the ratios of cell-associated DNA levels preadministration relative to postadministration of PRI-724 also did not reveal a difference between groups, thus suggesting a lack of effect of 12 weeks of PRI-724 treatment alone on the viral reservoir in our model. Due to our focus on estimating the size of the persistent SIV reservoir in subsets of memory CD4 ϩ T cells, we were restricted to the assessment of total cell-associated SIV DNA with available cell numbers. We recognize that this assay measures both intact and defective proviruses, thus overestimating the size of the replication-competent SIV reservoir. Future work using this antiproliferation, prodifferentiation approach should be designed to utilize quantitative virus outgrowth or intact proviral DNA assays (53) to understand the impact of the intervention on the replication-competent reservoir. Targeting additional pathways regulating the proliferation or differentiation of memory CD4 ϩ T cells, such as Notch or Hedgehog signaling pathways, is the subject of these ongoing studies. Using these approaches in combination with latency reversal agents and immunotherapeutics may be warranted to effectively reduce the size of the viral reservoir. A theoretically promising strategy would be to selectively promote the differentiation of latently infected memory CD4 ϩ T cells into shorter-lived cells that are more prone to die and are more susceptible to virus reactivation and immunemediated killing (54) .
In conclusion, our study established a safe dosage of the CBP/␤-catenin antagonist PRI-724 in ART-suppressed SIV-infected RMs. We showed that targeting Wnt signaling pathway can restrict the proliferation and promote the differentiation of long-lived memory CD4 ϩ T cells. To our knowledge, this is the first study targeting the selfrenewal properties of long-lived latently infected CD4 ϩ T cells as a key component of interventions aimed at reducing HIV/SIV persistence. This approach actively considers the structural and developmental heterogeneity of latently infected memory CD4 ϩ T cells, focusing a specific molecular strategy on a core feature of the viral reservoir that represents a substantial barrier to virus eradication. A transient block to the proliferation of long-lived latently infected memory CD4 ϩ T cells via selective inhibition of stem cell-like signaling pathways may represent a necessary and complementary approach to strategies directly targeting latent HIV.
MATERIALS AND METHODS
Animals and infection. Twelve Indian RMs (Macaca mulatta) with exclusion of Mamu B*08-and B*17-positive animals, were enrolled in this study. They were all infected i.v. with 10 3 TCID 50 of SIV mac251 and treated with ART before receiving or not receiving the experimental PRI-724 treatment. Concurrently, a PRI-724 dose-ranging study was performed in 11 healthy, uninfected Indian RMs. All animals were housed at the Yerkes National Primate Research Center (Atlanta, GA) and treated in accordance with Emory University and Yerkes National Primate Research Center Institutional Animal Care and Use Committee regulations. Antiretroviral therapy and PRI-724 treatment. The 12 SIV-infected RMs were treated with a potent 3-drug ART regimen initiated 11 days postinfection. The preformulated ART cocktail contained two reverse transcriptase inhibitors, 20 mg/ml tenofovir (TFV), and 40 mg/ml emtricitabine (FTC), plus 2.5 mg/ml of the integrase inhibitor dolutegravir (DTG). This ART cocktail was administered once daily at 1 ml/kg body weight via the subcutaneous (s.c.) route. PRI-724 was administered s.c. for up to 12 weeks at concentrations ranging from 10 to 80 mg/kg/day. Sample collection and processing. EDTA-anticoagulated blood samples were collected regularly and used for a complete blood count, routine chemical analysis, and immunostaining, with plasma separated by centrifugation within 1 h of phlebotomy. Peripheral blood mononuclear cells (PBMCs) were prepared by density gradient centrifugation and cryopreserved at Ϫ80°C until use.
Immunophenotyping by flow cytometry. Multicolor flow cytometric analysis was performed on whole blood or a cell suspension using predetermined optimal concentrations of the following fluorescently conjugated monoclonal antibodies (MAbs): CD3-APC-Cy7 (clone SP34-2), CD95-PE-Cy5 (clone DX2), K i -67-AF700 (clone B56), HLA-DR-PerCP-Cy5.5 (clone G46-6), CCR7-FITC (clone 150503), CCR5-APC (clone 3A9), and CD45RA-PECy7 (clone L48) from BD Biosciences; CD8-BV711 (clone RPA-T8), CD4-BV650 (clone OKT4), and PD-1-BV421 (clone EH12.2H7) from BioLegend, and CD28-ECD (clone CD28-2) from Beckman Coulter. Flow cytometric acquisition and analysis of samples were performed on at least 100,000 events on an LSR II flow cytometer driven by the FACSDiva software package (BD Biosciences). Analyses of the acquired data were performed using FlowJo version 10.0.4 software (TreeStar).
Cell sorting. After isolation, cells were resuspended in phosphate-buffered saline (PBS) containing 2 mM EDTA and spun for the removal of contaminating platelets. Prior to sorting, peripheral CD4 ϩ T cells were enriched with the use of magnetic beads and column purification (Miltenyi Biotec). Enriched peripheral CD4 ϩ T cells were then stained with previously determined volumes of the following fluorescently conjugated MAbs: CD3-APC-Cy7 or CD3-AF700 (clone SP34-2), CCR7-PE-Cy7 (clone 3D12), CD8-APC-Cy7 (clone SK1), CD45RA-APC (clone 5H9), CD95-PE-Cy5 (clone DX2), and
